Shao Jiangbo, Jin Ying, Jin Chunxiang
Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Department of Breast Surgery, The First Hospital of Jilin University, Changchun, Jilin, China.
Front Oncol. 2023 Aug 10;13:1210245. doi: 10.3389/fonc.2023.1210245. eCollection 2023.
Immunotherapy for immune response has ushered in a new era of cancer treatment. In recent years, new immunotherapeutic agents have been introduced into clinical trials and even approved for marketing. However, the widespread use of immunotherapeutic agents faces an unavoidable challenge: immunotherapy does not work at all for some patients, or has good efficacy in the initial phase, but immunotherapy resistance develops within a short period of time, and immunotherapy can also cause serious adverse effects such as autoimmune inflammation and non-specific inflammation. How to enable patients to overcome drug resistance, reduce the toxic side effects of drugs, enhance patient compliance and improve patient survival has become a problem that clinicians have to face. The advent of nanotechnology provides an encouraging platform for immunotherapy. It can not only improve the bioavailability and stability of drugs and reduce toxic side effects, but also reduce resistance to immunotherapy. Here, we discuss these research advances and discuss potential challenges and future directions.
针对免疫反应的免疫疗法开创了癌症治疗的新时代。近年来，新型免疫治疗药物已进入临床试验，甚至获批上市。然而，免疫治疗药物的广泛应用面临一个不可避免的挑战：免疫疗法对某些患者完全无效，或者在初始阶段疗效良好，但在短时间内就会产生免疫治疗耐药性，而且免疫疗法还会引发自身免疫性炎症和非特异性炎症等严重不良反应。如何使患者克服耐药性、降低药物的毒副作用、提高患者依从性并改善患者生存率，已成为临床医生不得不面对的问题。纳米技术的出现为免疫疗法提供了一个令人鼓舞的平台。它不仅可以提高药物的生物利用度和稳定性，降低毒副作用，还能降低对免疫疗法的耐药性。在此，我们讨论这些研究进展，并探讨潜在的挑战和未来方向。
